Adalimumab, Infliximab and Etanercept Biosimilars Market Analysis 2025–2029: Growth Forecast and Competitive Insights

Uncover key drivers, emerging technologies, and competitive movements shaping the adalimumab, infliximab and etanercept biosimilars market from 2025–2034 with trusted insights from The Business Research Company

How Much Will The Adalimumab, Infliximab and Etanercept Biosimilars Market Be Worth By 2029, And What CAGR Will It Achieve?

The adalimumab, infliximab and etanercept biosimilars market size has experienced rapid expansion in recent years. This market is projected to grow from $4.37 billion in 2024 to $4.96 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.6%. The growth observed in the historic period is attributable to elements such as increased healthcare expenditure, regulatory changes, regulatory changes, government initiatives, and rising healthcare costs.

The adalimumab, infliximab and etanercept biosimilars market is projected to experience substantial growth in the coming years. It is anticipated to reach $7.34 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.3%. This expansion during the forecast period is primarily driven by factors such as a rise in healthcare expenditure, an aging population, and increased access to healthcare. Furthermore, significant trends expected in the forecast period involve a concentrated effort on launching new products, engaging in mergers and acquisitions, establishing strategic partnerships, and increasing investments.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp

Which Factors Are Driving The Adalimumab, Infliximab and Etanercept Biosimilars Market Forward?

The ability of biosimilars to enter the adalimumab, infliximab, and etanercept biosimilars market stems from the patent expiration of branded drugs. For example, in the United States, following the patent expiry of the branded drug Remicade, the FDA gave its approval to Inflectra, developed by Hospira (a Pfizer Inc. company), for treating various autoimmune diseases such as rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis. Similarly, after Amgen’s Enbrel patent expired in the EU, Benepali (an Enbrel biosimilar) received approval from the European Commission. The patent for Humira also expired, leading to the availability of its biosimilars on the market. The FDA recently approved Hulio, which is the sixth biosimilar of Humira. Thus, the patent expiry of branded biologic drugs like Humira, Enbrel, and Remicade is expected to stimulate demand in the adalimumab, infliximab, and etanercept biosimilars market.

Which Segments Form The Key Structure Of The Adalimumab, Infliximab and Etanercept Biosimilars Market?

The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –

1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications

Subsegments:

1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others

2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others

3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development

What Strategic Shifts And Innovations Are Influencing The Adalimumab, Infliximab and Etanercept Biosimilars Market?

Leading companies in the adalimumab, infliximab, and etanercept biosimilars market are concentrating on developing innovative products, such as citrate-free adalimumab, to provide reliable services to customers. Citrate-free adalimumab is a formulation of the biological medication adalimumab that does not contain citrate. For instance, in December 2022, Fresenius Kabi, a Germany-based manufacturer of medicines and technologies for infusion, transfusion, and clinical nutrition, announced the FDA approval for biosimilar Idacio (adalimumab) for use in the management of chronic autoimmune disorders for all permissible uses of the reference product. It has been developed utilizing advanced analytical methods for application in the treatment of several chronic conditions.

Which Firms Are Making The Biggest Impact In The Adalimumab, Infliximab and Etanercept Biosimilars Market?

Major companies operating in the adalimumab, infliximab and etanercept biosimilars market include Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions, Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad, Roche, Bristol-Myers Squibb, Celon Pharma, SynBio, Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Mylan, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty) Ltd

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

Which Region Is Expected To Lead The Adalimumab, Infliximab and Etanercept Biosimilars Market In The Next Few Years?

North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2024. The regions covered in the adalimumab, infliximab, and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=3473&type=smp

Browse Through More Reports Similar to the Global Adalimumab, Infliximab and Etanercept Biosimilars Market 2025, By The Business Research Company

Oncology Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2025

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Trastuzumab Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795